🔴 Liquidia Technologies is trading 4.63% down in pre-market after court finds YUTREPIA infringes two patent claims

Liquidia Technologies is trading 4.63% down at $28.86 in pre-market on October 1 after a Delaware federal judge found YUTREPIA infringes two valid claims of a United Therapeutics patent covering treatment of pulmonary hypertension associated with interstitial lung disease.

• Reuters reported the ruling dealt a major blow to YUTREPIA’s commercial outlook.
• Liquidia plans to appeal and will ask the FDA to remove the PH-ILD indication from YUTREPIA’s label.
• Final judgment is expected in about a week; potential remedies are still to be determined.